LYVE1 and hepatocellular carcinoma: In addition, endothelial trans-differentiation, characterized by sprouting angiogenesis and loss of LSEC markers (stabilin-1, stabilin-2, lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) and CD32b) is a hallmark of HCC progression in both murine and human studies.